Payment overview · 2025
General Payments
$1,159.50
64 reported records · 12 companies
Healthcare provider profile · identity verified
William E Parrish, MD
Allopathic & Osteopathic Physicians|Family Medicine · BREMEN, GA · NPI 1609880707
Verified facts
What the public records show
CMS Open Payments records show William E Parrish, MD received $1,159.50 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Qulipta, Rybelsus, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 601 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $314.82 | 27.1% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.13 | 16.8% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $155.30 | 13.4% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.74 | 10.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.55 | 5.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.34 | 5.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.98 | 4.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $54.67 | 4.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.53 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.01 | 3.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.77 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.66 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,159.50 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $155.30 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $155.30 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.84 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $141.84 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.73 | 12 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $126.74 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.55 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $56.40 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.98 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.98 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $54.67 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.12 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 601 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 239 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 292 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 339 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
126 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
239 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
239 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
292 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
339 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
601 | 115 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 37 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1778 | 426 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1386 | 315 |
| Amlodipine Besylate | Amlodipine Besylate | 1174 | 297 |
| Metoprolol Succinate | Metoprolol Succinate | 1144 | 274 |
| Pantoprazole Sodium | Pantoprazole Sodium | 830 | 213 |
| Gabapentin | Gabapentin | 774 | 192 |
| Omeprazole | Omeprazole | 771 | 200 |
| Lisinopril | Lisinopril | 760 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 677 | 166 |
| Eliquis | Apixaban | 601 | 115 |
| Fluticasone Propionate | Fluticasone Propionate | 601 | 247 |
| Losartan Potassium | Losartan Potassium | 594 | 155 |
| Duloxetine Hcl | Duloxetine Hcl | 574 | 144 |
| Mirtazapine | Mirtazapine | 547 | 131 |
| Furosemide | Furosemide | 510 | 153 |
| Hydrochlorothiazide | Hydrochlorothiazide | 482 | 121 |
| Famotidine | Famotidine | 481 | 133 |
| Metformin Hcl Er | Metformin Hcl | 478 | 127 |
| Ezetimibe | Ezetimibe | 475 | 119 |
| Potassium Chloride | Potassium Chloride | 463 | 119 |
| Ramipril | Ramipril | 454 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 433 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 430 | 120 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 411 | 71 |
| Buspirone Hcl | Buspirone Hcl | 381 | 88 |
| Prednisone | Prednisone | 376 | 250 |
| Trazodone Hcl | Trazodone Hcl | 362 | 90 |
| Ozempic | Semaglutide | 339 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 335 | 79 |
| Sertraline Hcl | Sertraline Hcl | 324 | 89 |
| Tramadol Hcl | Tramadol Hcl | 314 | 78 |
| Glimepiride | Glimepiride | 313 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 310 | 81 |
| Carvedilol | Carvedilol | 300 | 73 |
| Mounjaro | Tirzepatide | 292 | 48 |
| Pregabalin | Pregabalin | 276 | 68 |
| Nebivolol Hcl | Nebivolol Hcl | 269 | 61 |
| Farxiga | Dapagliflozin Propanediol | 263 | 40 |
| Meloxicam | Meloxicam | 262 | 70 |
| Clonazepam | Clonazepam | 252 | 35 |
| Montelukast Sodium | Montelukast Sodium | 250 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 244 | 39 |
| Jardiance | Empagliflozin | 239 | 55 |
| Azithromycin | Azithromycin | 235 | 176 |
| Simvastatin | Simvastatin | 234 | 66 |
| Metformin Hcl | Metformin Hcl | 232 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 231 | 59 |
| Ondansetron Odt | Ondansetron | 227 | 93 |
| Donepezil Hcl | Donepezil Hcl | 224 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 221 | 59 |
| Allopurinol | Allopurinol | 212 | 52 |
| Lovastatin | Lovastatin | 211 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 195 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 191 | 41 |
| Spironolactone | Spironolactone | 188 | 50 |
| Lorazepam | Lorazepam | 185 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 52 |
| Temazepam | Temazepam | 184 | 41 |
| Bupropion Xl | Bupropion Hcl | 173 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 26 |
| Atenolol | Atenolol | 162 | 39 |
| Alprazolam | Alprazolam | 161 | 30 |
| Glipizide Er | Glipizide | 157 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 153 | 35 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 152 | 35 |
| Celecoxib | Celecoxib | 139 | 37 |
| Topiramate | Topiramate | 136 | 32 |
| Valsartan | Valsartan | 135 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 36 |
| Promethazine Hcl | Promethazine Hcl | 133 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 132 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 75 |
| Linzess | Linaclotide | 126 | 34 |
| Memantine Hcl | Memantine Hcl | 126 | 34 |
| Myrbetriq | Mirabegron | 122 | 26 |
| Nystatin | Nystatin | 122 | 64 |
| Doxycycline Hyclate | Doxycycline Hyclate | 121 | 95 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 118 | 29 |
| Fluconazole | Fluconazole | 118 | 61 |
| Xarelto | Rivaroxaban | 115 | 24 |
| Baclofen | Baclofen | 114 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 112 | 31 |
| Cephalexin | Cephalexin | 107 | 84 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 22 |
| Terazosin Hcl | Terazosin Hcl | 104 | 24 |
| Solifenacin Succinate | Solifenacin Succinate | 102 | 28 |
| Synthroid | Levothyroxine Sodium | 98 | 20 |
| Varenicline Tartrate | Varenicline Tartrate | 98 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 31 |
| Azelastine Hcl | Azelastine Hcl | 92 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 74 |
| Meclizine Hcl | Meclizine Hcl | 91 | 38 |
| Sucralfate | Sucralfate | 90 | 31 |
| Amoxicillin | Amoxicillin | 88 | 68 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 25 |
| Trulicity | Dulaglutide | 85 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 24 |
| Finasteride | Finasteride | 78 | 26 |
| Levetiracetam | Levetiracetam | 75 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 73 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 57 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 72 | 72 |
| Divalproex Sodium | Divalproex Sodium | 72 | 16 |
| Methocarbamol | Methocarbamol | 72 | 30 |
| Doxepin Hcl | Doxepin Hcl | 71 | 18 |
| Fenofibrate | Fenofibrate | 70 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | 14 |
| Lamotrigine | Lamotrigine | 68 | 19 |
| Benazepril Hcl | Benazepril Hcl | 67 | 18 |
| Dexamethasone | Dexamethasone | 66 | 65 |
| Klor-Con M10 | Potassium Chloride | 66 | 20 |
| Naloxone Hcl | Naloxone Hcl | 66 | 53 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 56 |
| Primidone | Primidone | 62 | 15 |
| Propranolol Hcl | Propranolol Hcl | 62 | 12 |
| Diazepam | Diazepam | 61 | 12 |
| Gemtesa | Vibegron | 61 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 13 |
| Entresto | Sacubitril/Valsartan | 59 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 57 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 17 |
| Febuxostat | Febuxostat | 56 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 56 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 19 |
| Aripiprazole | Aripiprazole | 55 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 55 | suppressed |
| Cefdinir | Cefdinir | 54 | 46 |
| Ciclopirox | Ciclopirox Olamine | 54 | 25 |
| Clonidine Hcl | Clonidine Hcl | 54 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 54 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 12 |
| Estradiol | Estradiol | 52 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | suppressed |
| Ibuprofen | Ibuprofen | 51 | 17 |
| Risperidone | Risperidone | 51 | suppressed |
| Buprenorphine | Buprenorphine | 49 | 12 |
| Repatha Sureclick | Evolocumab | 49 | 11 |
| Nifedipine Er | Nifedipine | 48 | 11 |
| Warfarin Sodium | Warfarin Sodium | 48 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 46 | suppressed |
| Lansoprazole | Lansoprazole | 46 | 12 |
| Lubiprostone | Lubiprostone | 46 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 17 |
| Chlorthalidone | Chlorthalidone | 44 | 12 |
| Novolog Flexpen | Insulin Aspart | 44 | 13 |
| Zonisamide | Zonisamide | 44 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | suppressed |
| Metronidazole | Metronidazole | 43 | 38 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 41 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 18 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 39 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 37 |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Telmisartan | Telmisartan | 37 | suppressed |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 16 |
| Dutasteride | Dutasteride | 35 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 35 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 16 |
| Felodipine Er | Felodipine | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | 11 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 12 |
| Ketoconazole | Ketoconazole | 28 | 11 |
| Nitroglycerin | Nitroglycerin | 28 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 11 |
| Torsemide | Torsemide | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ubrelvy | Ubrogepant | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 15 |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 11 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Belbuca | Buprenorphine Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Danazol | Danazol | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,159.50 · 64 records | Novo Nordisk Inc | Auvelity, CAPLYTA, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error